Medullary Thyroid Cancer is a rare form of thyroid malignancy that arises from parafollicular C cells of the thyroid gland, which are responsible for producing the hormone calcitonin. Unlike other thyroid cancers that originate from follicular cells, this cancer has unique biological behavior and genetic characteristics. Advances in understanding this disease are often presented at major international scientific forums such as a Cancer Conference, where specialists discuss new developments in diagnosis, targeted treatment, and long-term management strategies for medullary thyroid carcinoma.

Medullary thyroid cancer can occur either sporadically or as part of inherited genetic syndromes. Sporadic cases represent the majority of diagnoses and arise from acquired genetic mutations affecting cellular growth regulation. However, a significant proportion of cases are associated with hereditary syndromes linked to mutations in the RET proto-oncogene. These inherited forms may occur as part of multiple endocrine neoplasia syndromes and can affect several endocrine organs simultaneously. Genetic testing has therefore become an essential component of diagnosis and family risk assessment, allowing clinicians to identify individuals who may benefit from early monitoring or preventive treatment.

The clinical presentation of medullary thyroid cancer may vary depending on tumor size and disease progression. Patients may initially notice a painless lump or swelling in the neck caused by a growing thyroid tumor. Because C cells produce calcitonin, elevated levels of this hormone in blood tests can serve as an important biomarker for diagnosis and disease monitoring. Additional symptoms may include difficulty swallowing, voice changes, or enlarged lymph nodes in the neck if the tumor spreads locally. Imaging studies, fine-needle aspiration biopsy, and laboratory testing are typically used together to confirm the diagnosis and determine disease stage.

Treatment strategies for medullary thyroid cancer focus primarily on surgical removal of the thyroid gland and affected lymph nodes. Unlike some other thyroid cancers, this subtype does not respond well to radioactive iodine therapy because C cells do not absorb iodine. For patients with advanced or metastatic disease, targeted therapies that inhibit RET signaling pathways have become an important treatment option. These therapies are designed to block molecular signals that promote tumor growth and spread. Ongoing research continues to investigate new targeted drugs, biomarkers, and genetic testing strategies that may improve early detection, personalized treatment planning, and long-term outcomes for individuals diagnosed with medullary thyroid cancer.